reference/16841571

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16841571

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Journal Article\|Multicenter Study
endingPage	1017
issn	1349-7006 1347-9032
issueIdentifier	7
pageRange	1013-1017
publicationName	Cancer Science
startingPage	1013
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4b711ffdbe8af5c8f3f9c53da46d83fa http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c1b9f1c2d5cc1361ccf28b0108bd7179 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b57aef90ae010dccd0e5949894e3295b
bibliographicCitation	Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S. Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy. Cancer Sci. 2016 Jul;107(7):1013–7. PMID: 27089226; PMCID: PMC4946720.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a2c155cfabfac96eb41c573b038bc3fd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_36f1a1157b429f31664a5c10dabdf1dc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1a99264d1ff68ea58460cff0e65cefa1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e55ef431070d6ef582129d4b7dee1b4a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_750e27ff50a198843644793502b2e583 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cfd020af06b47346c91a4bcde434de9e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_87a03b162b11b996a593a3af8264ee41 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ca9f98f0b823010e41933e0a1374962e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_57a5c1fc27b9a2bbd9011ad64f235778 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dced2d91cc1d739b979454e2f3e4484c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6bac9d6b9b45439a578066d13549aa81 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b672ba1e3c98e9b724af759161be39e5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_55ad0f78b8f86d64abef007bd5531501 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_144df77361ae59972ffac358167e9216 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8300fdf109780702dda956ce46a6f3bb
date	2016-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/27089226 https://pubmed.ncbi.nlm.nih.gov/PMC4946720 https://doi.org/10.1111/cas.12951
isPartOf	https://portal.issn.org/resource/ISSN/1349-7006 https://portal.issn.org/resource/ISSN/1347-9032 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/30320
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
discusses	http://id.nlm.nih.gov/mesh/M0229085 http://id.nlm.nih.gov/mesh/M0477916 http://id.nlm.nih.gov/mesh/M0025711 http://id.nlm.nih.gov/mesh/M0001483
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D007680Q000188 http://id.nlm.nih.gov/mesh/D016898Q000627 http://id.nlm.nih.gov/mesh/D016898Q000008 http://id.nlm.nih.gov/mesh/D058990 http://id.nlm.nih.gov/mesh/D002292Q000188 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D000970Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D015996 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D007680Q000473 http://id.nlm.nih.gov/mesh/D050796Q000235 http://id.nlm.nih.gov/mesh/D007680Q000235 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D016022 http://id.nlm.nih.gov/mesh/D002292Q000235 http://id.nlm.nih.gov/mesh/D015331 http://id.nlm.nih.gov/mesh/D009362 http://id.nlm.nih.gov/mesh/D002292Q000473 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D020641Q000235
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_132a8504e7423e57e5565c4615cd0cd2 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_a7939d043567ee90a9f1febb314e563d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8063 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8382

Total number of triples: 75.